Physician profile
Isteaq Ahmed
NPI 1245525765
$2,912.34
in general payments reported to CMS, 2019-2025
12 companies · $678 in 2025
The $678 reported for 2025 was more than what 85% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $624 · 2023: $857 · 2024: $629 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,095.48 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,155.26 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $387.85 | 2023-2025 | Vraylar |
| Indivior INC. | $385.65 | 2022-2025 | Sublocade |
| Braeburn INC. | $312.24 | 2023-2025 | Brixadi |
| Axsome Therapeutics, INC. | $196.95 | 2024-2025 | Auvelity |
| Alkermes, INC. | $134.45 | 2022-2024 | Vivitrol |
| Janssen Pharmaceuticals, INC | $112.60 | 2023 | Spravato |
| Hikma Pharmaceuticals USA | $97.93 | 2021-2022 | |
| Uswm, LLC | $56.55 | 2022-2023 | Zimhi, Lucemyra |
| Orexo US, INC. | $39.30 | 2022 | |
| Vanda Pharmaceuticals INC. | $19.93 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.63 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isteaq Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.